Spiriva Respimat approved in EU for Asthma treatment- Boehringer
Boehringer Ingelheim announced that the indication for Spiriva (tiotropium) Respimat in Asthma has been accepted by the regulatory authorities in the EU. Spiriva Respimat is indicated as an add-on maintenance bronchodilator treatment in adult patients with Asthma who are currently treated with the maintenance combination of inhaled corticosteroids and long-acting beta2-agonists and who experienced one or more severe exacerbations in the previous year.
The new indication for Spiriva Respimat in asthma is based on the UniTinA-asthma large-scale, Phase III clinical trial programme which investigated adults with Asthma who continued to have symptoms despite taking at least ICS or ICS/LABA therapy.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.